Literature DB >> 16547169

Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of cAMP-dependent protein kinase-mediated maxi-K channel activation.

So Youn Park1, Jeong Hyun Lee, Chi Dae Kim, Won Suk Lee, Won Sun Park, Jin Han, Yong-Geun Kwak, Ki Young Kim, Ki Whan Hong.   

Abstract

This study shows whether increased intracellular cAMP level by cilostazol is directly coupled to its maxi-K channel activation in human endothelial cells. Cilostazol (1 microM) increased the K+ currents in the human endothelial cells by activating maxi-K channels, which was abolished by iberiotoxin (100 nM), a maxi-K channel blocker. On incubation of human coronary artery endothelial cells with tumor necrosis factor-alpha (TNF-alpha) (50 ng/ml), monocyte adhesion significantly increased with increased superoxide generation and expression of vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1) accompanied by increased degradation of inhibitory kappaBalpha in cytoplasm and activation of nuclear factor-kappaB p65 in nucleus. All these variables were significantly suppressed by cilostazol (10 microM), which was antagonized by iberiotoxin (1 microM) and (9R,10S,12S)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-l] [1,6]benzodiazocine-10-carboxylic acid hexyl ester (KT 5720) (300 nM, cAMP-dependent protein kinase inhibitor), but not by (9S,10R,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-9,12-epoxy-1H-diindo-lo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-I][1,6]benzodiazocine-10-carboxylic acid methyl ester (KT 5823) (300 nM, cGMP-dependent protein kinase inhibitor). In the human endothelial cells transfected with siRNA-targeting maxi-K channels, cilostazol did not suppress the superoxide generation, VCAM-1 and MCP-1 expressions, and monocyte adhesion as contrasted with the wild-type cells. These findings were similarly evident with (3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indole-2-one (BMS-204352), a maxi-K channel opener, and forskolin and dibutyryl cAMP. In conclusion, increased cAMP level by cilostazol is directly coupled to its maxi-K channel opening action via protein kinase activation in human endothelial cells, thereby suppressing TNF-alpha-stimulated superoxide production and expression of adhesion molecules.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16547169     DOI: 10.1124/jpet.105.098509

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

Review 1.  Calcium-activated potassium channels and endothelial dysfunction: therapeutic options?

Authors:  Michel Félétou
Journal:  Br J Pharmacol       Date:  2009-01-29       Impact factor: 8.739

2.  Cilostazol add-on therapy for celecoxib synergistically inhibits proinflammatory cytokines by activating IL-10 and SOCS3 in the synovial fibroblasts of patients with rheumatoid arthritis.

Authors:  Yi Sle Lee; Sang Yeob Lee; So Youn Park; Sung Won Lee; Ki Whan Hong; Chi Dae Kim
Journal:  Inflammopharmacology       Date:  2019-05-23       Impact factor: 4.473

3.  Beneficial effect of anti-platelet therapies on atherosclerotic lesion formation assessed by phase-contrast X-ray CT imaging.

Authors:  Masafumi Takeda; Tomoya Yamashita; Masakazu Shinohara; Naoto Sasaki; Hideto Tawa; Kenji Nakajima; Atsushi Momose; Ken-Ichi Hirata
Journal:  Int J Cardiovasc Imaging       Date:  2011-06-19       Impact factor: 2.357

4.  Comparative effects of cilostazol and aspirin on the impairment of endothelium-dependent cerebral vasodilation caused by acute cigarette smoking in rats.

Authors:  Hiroki Iida; Mami Iida; Motoyasu Takenaka; Naokazu Fukuoka; Shuji Dohi
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

Review 5.  Targeting BKCa Channels in Migraine: Rationale and Perspectives.

Authors:  Mohammad Al-Mahdi Al-Karagholi; Christian Gram; Cherie Amalie Waldorff Nielsen; Messoud Ashina
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

6.  Synergistic efficacy of concurrent treatment with cilostazol and probucol on the suppression of reactive oxygen species and inflammatory markers in cultured human coronary artery endothelial cells.

Authors:  So Youn Park; Jeong Hyun Lee; Hwa Kyoung Shin; Chi Dae Kim; Won Suk Lee; Byung Yong Rhim; Yung Woo Shin; Ki Whan Hong
Journal:  Korean J Physiol Pharmacol       Date:  2008-08-31       Impact factor: 2.016

7.  Role of the BK channel (KCa1.1) during activation of electrogenic K+ secretion in guinea pig distal colon.

Authors:  Jin Zhang; Susan T Halm; Dan R Halm
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-10-11       Impact factor: 4.052

8.  Suppression of PU.1-linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from patients with rheumatoid arthritis.

Authors:  S Y Park; S W Lee; S H Baek; C W Lee; W S Lee; B Y Rhim; K W Hong; C D Kim
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

9.  CK2 is a novel negative regulator of NADPH oxidase and a neuroprotectant in mice after cerebral ischemia.

Authors:  Gab Seok Kim; Joo Eun Jung; Kuniyasu Niizuma; Pak H Chan
Journal:  J Neurosci       Date:  2009-11-25       Impact factor: 6.167

Review 10.  Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.

Authors:  Jeong Hyun Lee; So Youn Park; Hwa Kyoung Shin; Chi Dae Kim; Won Suk Lee; Ki Whan Hong
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.